Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

Christoph Röcken

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6989-8002; OpenAlex author ID A5024583139, A5063499277. Sources: OpenAlex.

Their work

Papers
27 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
73
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 27

  1. Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119257↗
  2. Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-026-01663-z↗
  3. L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma Co-author DOI 10.64898/2026.08.10.743835↗
  4. Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling. Co-author DOI 10.1097/cji.0000000000000572↗
  5. Transmembrane Protease Serine 11B Modulates Lactate Transport Through SLC16A1 in Pancreatic Ductal Adenocarcinoma-A Functional Link to Phenotype Heterogeneity. Co-author DOI 10.3390/ijms26115398↗
  6. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-022-05535-9↗
  7. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2023.1157397↗
  8. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarci… Co-author DOI 10.3389/fonc.2023.1160824↗
  9. Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194605↗
  10. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression. Co-author DOI 10.1007/s00432-021-03745-w↗
  11. Insulin Receptor in Pancreatic Cancer-Crown Witness in Cross Examination. Last author DOI 10.3390/cancers13194988↗
  12. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control. Co-author DOI 10.3390/medsci9030048↗
  13. Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells †. Co-author DOI 10.3390/cancers12030581↗
  14. The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma. Co-author DOI 10.14670/hh-18-054↗
  15. POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.26705↗
  16. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Co-author DOI 10.1038/s41419-018-0478-0↗
  17. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC. Co-author DOI 10.1186/s12885-018-4688-8↗
  18. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1368603↗
  19. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.pan.2016.07.008↗
  20. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Co-author DOI 10.1002/ijc.29445↗
  21. CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T ce… Co-author DOI 10.1080/2162402x.2014.1000083↗
  22. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Co-author DOI 10.1016/j.molonc.2014.03.001↗
  23. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-13-0675↗
  24. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0094357↗
  25. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  26. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2012.18↗
  27. Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0046002↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susanne Sebens · 18 shared papers, 2014–2026 · strength 2.44
  2. H. Schäfer · 11 shared papers, 2014–2025 · strength 1.32
  3. Tina Daunke · 6 shared papers, 2021–2026 · strength 1.11
  4. Silje Beckinger · 6 shared papers, 2021–2026 · strength 1.11
  5. Daniela Wesch · 10 shared papers, 2014–2026 · strength 1.09
  6. Anna Maxi Wandmacher · 4 shared papers, 2023–2026 · strength 0.85
  7. Rüdiger Braun · 3 shared papers, 2026 · strength 0.69
  8. Annika Bräuer · 3 shared papers, 2026 · strength 0.69
  9. Jan-Paul Gundlach · 5 shared papers, 2017–2026 · strength 0.66
  10. Anna Trauzold · 5 shared papers, 2018–2025 · strength 0.65
  11. Anne‐Sophie Mehdorn · 3 shared papers, 2022–2026 · strength 0.60
  12. Steffen Markus Heckl · 4 shared papers, 2021–2023 · strength 0.60
  13. Holger Kalthoff · 6 shared papers, 2014–2021 · strength 0.46
  14. Benjamin Heckelmann · 2 shared papers, 2026 · strength 0.46
  15. Claudia Geismann · 2 shared papers, 2023–2025 · strength 0.43
  16. Sascha Rahn · 3 shared papers, 2019–2023 · strength 0.43
  17. Christian Röder · 4 shared papers, 2014–2021 · strength 0.35
  18. Alexander Arlt · 2 shared papers, 2020–2023 · strength 0.29
  19. Hermann B. Frieboes · 1 shared paper, 2025 · strength 0.28
  20. Dylan A. Goodin · 1 shared paper, 2025 · strength 0.28
  21. Dinara M. Baiskhanova · 1 shared paper, 2025 · strength 0.27
  22. Rainer Lothar Heuchel · 1 shared paper, 2026 · strength 0.24
  23. Tobias Keck · 1 shared paper, 2026 · strength 0.22
  24. Louisa Bolm · 1 shared paper, 2026 · strength 0.22
  25. Corinna Ulrike Keber · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.